logo-loader

Arecor

Receive alerts
Market:
Unlisted (UK)
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

Arecor is ‘advancing today’s therapies to enable healthier lives’ by developing a broad portfolio of therapies for its proprietary pipeline and in partnership with leading pharmaceutical and biotech companies

Deep dive We explore the investor case for growth companies

Snapshot

  • Arecor uses its ground-breaking technology platform, Arestat™ to develop future medicines from existing therapies, across all disease indications and at any stage of a drug lifecycle
  • Proprietary portfolio includes first franchise in diabetes and has expanded its development pipeline into anti-infectives
  • Partners with leading pharmaceutical and biotech companies to improve their products, find solutions or create next-generation products

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Arecor punches above its weight with trials for fast-acting diabetes drugs

Investors are placing bets on a small British biotech to rival big pharma as it pushes its first diabetes drug through clinical trials

on 14/11/19